Roche hands Chinese biotech $70M for HER2 drug that can go to the brain
Roche is still hunting for next-generation drugs that can hit HER2-positive cancer, and it’s found a Phase I candidate it likes from a Chinese biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
